These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

223 related articles for article (PubMed ID: 20493430)

  • 1. Comparison of the effects of three angiotensin II receptor type 1 blockers on metabolic parameters in hypertensive patients with type 2 diabetes mellitus.
    Ozaki N; Nomura Y; Sobajima H; Kondo K; Oiso Y
    Eur J Intern Med; 2010 Jun; 21(3):236-9. PubMed ID: 20493430
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antiproteinuric effects of angiotensin receptor blockers: telmisartan versus valsartan in hypertensive patients with type 2 diabetes mellitus and overt nephropathy.
    Galle J; Schwedhelm E; Pinnetti S; Böger RH; Wanner C;
    Nephrol Dial Transplant; 2008 Oct; 23(10):3174-83. PubMed ID: 18450829
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Metabolic effects of telmisartan and irbesartan in type 2 diabetic patients with metabolic syndrome treated with rosiglitazone.
    Derosa G; Fogari E; D'Angelo A; Cicero AF; Salvadeo SA; Ragonesi PD; Ferrari I; Gravina A; Fassi R; Fogari R
    J Clin Pharm Ther; 2007 Jun; 32(3):261-8. PubMed ID: 17489878
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Improvement of endothelial function in patients with hypertension and type 2 diabetes after treatment with telmisartan.
    Wago T; Yoshimoto T; Akaza I; Tsuchiya K; Izumiyama H; Doi M; Hirata Y
    Hypertens Res; 2010 Aug; 33(8):796-801. PubMed ID: 20555330
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Telmisartan but not candesartan affects adiponectin expression in vivo and in vitro.
    Yamada S; Ano N; Toda K; Kitaoka A; Shiono K; Inoue G; Atsuda K; Irie J
    Hypertens Res; 2008 Apr; 31(4):601-6. PubMed ID: 18633170
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparative effect of angiotensin II type I receptor blockers on serum uric acid in hypertensive patients with type 2 diabetes mellitus: a retrospective observational study.
    Nishida Y; Takahashi Y; Susa N; Kanou N; Nakayama T; Asai S
    Cardiovasc Diabetol; 2013 Nov; 12():159. PubMed ID: 24180232
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of the efficacy and safety profiles of two fixed-dose combinations of antihypertensive agents, amlodipine/benazepril versus valsartan/hydrochlorothiazide, in patients with type 2 diabetes mellitus and hypertension: a 16-week, multicenter, randomized, double-blind, noninferiority study.
    Lee IT; Hung YJ; Chen JF; Wang CY; Lee WJ; Sheu WH
    Clin Ther; 2012 Aug; 34(8):1735-50. PubMed ID: 22784975
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Valsartan vs. other angiotensin II receptor blockers in the treatment of hypertension: a meta-analytical approach.
    Nixon RM; Müller E; Lowy A; Falvey H
    Int J Clin Pract; 2009 May; 63(5):766-75. PubMed ID: 19392925
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Replacement of valsartan and candesartan by telmisartan in hypertensive patients with type 2 diabetes: metabolic and antiatherogenic consequences.
    Miura Y; Yamamoto N; Tsunekawa S; Taguchi S; Eguchi Y; Ozaki N; Oiso Y
    Diabetes Care; 2005 Mar; 28(3):757-8. PubMed ID: 15735228
    [No Abstract]   [Full Text] [Related]  

  • 10. Effects of telmisartan on adiponectin levels and body weight in hypertensive patients with glucose intolerance.
    Makita S; Abiko A; Naganuma Y; Moriai Y; Nakamura M
    Metabolism; 2008 Oct; 57(10):1473-8. PubMed ID: 18803955
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety of combination therapy using high- or low-dose hydrochlorothiazide with valsartan or other Angiotensin-receptor blockers.
    Fuenfstueck R; Hempel RD; Ansari A; Weidinger G; Klebs S
    Adv Ther; 2005; 22(3):263-77. PubMed ID: 16236687
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Telmisartan improves lipid metabolism and adiponectin production but does not affect glycemic control in hypertensive patients with type 2 diabetes.
    Mori Y; Itoh Y; Tajima N
    Adv Ther; 2007; 24(1):146-53. PubMed ID: 17526471
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of the angiotensin II receptor blockers telmisartan versus valsartan in combination with hydrochlorothiazide: a large, confirmatory trial.
    White WB; Murwin D; Chrysant SG; Koval SE; Davidai G; Guthrie R
    Blood Press Monit; 2008 Feb; 13(1):21-7. PubMed ID: 18199920
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antihypertensive and metabolic effects of high-dose olmesartan and telmisartan in type 2 diabetes patients with hypertension.
    Arao T; Okada Y; Mori H; Nishida K; Tanaka Y
    Endocr J; 2013; 60(5):563-70. PubMed ID: 23303198
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Telmisartan at 80 mg/day increases high-molecular-weight adiponectin levels and improves insulin resistance in diabetic patients.
    Mori H; Okada Y; Arao T; Nishida K; Tanaka Y
    Adv Ther; 2012 Jul; 29(7):635-44. PubMed ID: 22821644
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of the angiotensin II receptor blockers telmisartan versus valsartan on the circadian variation of blood pressure: impact on the early morning period.
    White WB; Lacourciere Y; Davidai G
    Am J Hypertens; 2004 Apr; 17(4):347-53. PubMed ID: 15062889
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of co-administration of candesartan with pioglitazone on inflammatory parameters in hypertensive patients with type 2 diabetes mellitus: a preliminary report.
    Suzuki H; Sakamoto M; Hayashi T; Iuchi H; Ohashi K; Isaka T; Sakamoto N; Kayama Y; Tojo K; Yoshimura M; Utsunomiya K
    Cardiovasc Diabetol; 2013 May; 12():71. PubMed ID: 23635096
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Telmisartan or valsartan alone or in combination with hydrochlorothiazide: a review.
    Lacourcière Y
    Clin Exp Hypertens; 2013; 35(1):50-60. PubMed ID: 22866964
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Beneficial cardiometabolic actions of telmisartan plus amlodipine therapy in elderly patients with poorly controlled hypertension.
    Bekki H; Yamamoto K; Sone M; Homma T; Nakata M; Nohara M; Fukami K; Okuda S; Yamagishi S
    Clin Cardiol; 2011 Apr; 34(4):261-5. PubMed ID: 21432858
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Telmisartan reduces neointima volume and pulse wave velocity 8 months after zotarolimus-eluting stent implantation in hypertensive type 2 diabetic patients.
    Hong SJ; Choi SC; Ahn CM; Park JH; Kim JS; Lim DS
    Heart; 2011 Sep; 97(17):1425-32. PubMed ID: 21700754
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.